Healthcare / BiotechnologyNYSE American
$0.21
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF n/d · quality 66.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
12/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$3M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-529.6%
↓Gross Margin
N/A
•Debt/Equity
0.16
↓Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-19.9M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | — | — | — | — | $45000.00 | — |
| Net Income | $-19.9M | $-19.9M | $-22.1M | $-29.2M | $-25.4M | — |
| EBITDA | $-18.6M | $-18.6M | $-20.2M | — | — | — |
| EPS | -5.95 | -5.95 | -35.70 | -17.33 | 2.99 | — |
| Operating Margin | — | — | — | — | -51395.6% | — |
| Net Margin | — | — | — | — | -56504.4% | — |
| Balance Sheet | ||||||
| Debt/Equity | 0.16 | 0.16 | 0.39 | -0.25 | — | — |
| Returns | ||||||
| ROE | -529.6% | -529.6% | -1443.5% | 354.8% | 50.4% | — |
| Growth & Yield | ||||||
| EPS Growth | 83.3% | 83.3% | -106.0% | -679.6% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.